Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis.
about
Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathwayChanges in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.
P2860
Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@en
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@nl
type
label
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@en
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@nl
prefLabel
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@en
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@nl
P2093
P2860
P1476
Serum macrophage migration inh ...... nts with rheumatoid arthritis.
@en
P2093
Hidekazu Furuya
Hiroyuki Tsukamoto
Katsunori Inagaki
Masanori Nakamura
Masayu Umemura
Ryo Takahashi
Sakiko Isojima
Takehiro Tokunaga
Tsuyoshi Kasama
P2860
P2888
P304
P356
10.1007/S00296-013-2778-0
P577
2013-05-14T00:00:00Z